Gavin Choy - 31 Dec 2021 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Reporting relationship: Acting Chief Financial Officer
Issuer ticker: GTBP
Reported as of: 31 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Feb 2022, 15:09:22 UTC
Prior SEC filing: 14 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Gavin Choy

Key filing fact

Gavin Choy filed Form 4 for GT Biopharma, Inc. (GTBP) on 14 Feb 2022.

Key facts

This page summarizes Gavin Choy's Form 4 filing for GT Biopharma, Inc. (GTBP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Feb 2022, 15:09.

Change

Previous filing in this sequence was filed on 14 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GTBP transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $0
Shares: +227,500
Change %
Price: $0.000000
Shares after: 227,500
Date: 31 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 227,500
Exercise price: $3.05
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

33% on the date of grant, 33% on 6/1/22 and 34% on 6/1/23, subject to continued service and subject to full acceleration immediately prior to the consummation of a change of control.